Fulgent Genetics Inc. (FLGT)
Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
Fulgent Genetics' core revenue grew just 3% in H1 2024, with full-year guidance of $280 million implying a step-up to 11% growth in H2 and 7% for FY 2024. Growth in precision diagnostics (+35% in H1 2024) and gross margin expansion (+650 basis points) were the two bright spots in first half results. Headwinds in anatomic pathology and BioPharma services will soften starting H2 2024, paving the way for core growth re-acceleration and operating margin improvements.
Fulgent Genetics (FLGT) Upgraded to Buy: What Does It Mean for the Stock?
Fulgent Genetics (FLGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22%
The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 27.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.08 per share a year ago.
Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?
Fulgent Genetics (FLGT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
